A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients
In plain words A Phase 1 study of troxerutin in people 18 and older, run by Westlake University. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: COVID 19 Associated Coagulopathy.
- Respiratory rate ≥30 breaths/min
- Severe respiratory distress
- Oxygen saturation (SpO₂) ≤90% in room air
- Progressive deterioration of clinical symptoms with lung imaging showing significant progression of lesions (>50%) within 24 to 48 hours.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Troxerutin; Placebo; placebo + low molecular weight heparin; troxerutin + low molecular weight heparin
Registered summary
The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are: * Does troxerutin lower the number of thrombotic events in participants? * What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients. The full summary is on the listing.
Where, as registered
No US site; China (1).